News
EDSA
1.912
-2.14%
-0.042
Edesa Biotech Inc <EDSA.OQ> expected to post a loss of 31 cents a share - Earnings Preview
Reuters · 4d ago
Weekly Report: what happened at EDSA last week (0127-0131)?
Weekly Report · 6d ago
Weekly Report: what happened at EDSA last week (0120-0124)?
Weekly Report · 01/27 10:56
Weekly Report: what happened at EDSA last week (0113-0117)?
Weekly Report · 01/20 10:49
Weekly Report: what happened at EDSA last week (0106-0110)?
Weekly Report · 01/13 10:49
Weekly Report: what happened at EDSA last week (1230-0103)?
Weekly Report · 01/06 10:56
Weekly Report: what happened at EDSA last week (1223-1227)?
Weekly Report · 12/30/2024 10:51
Weekly Report: what happened at EDSA last week (1216-1220)?
Weekly Report · 12/23/2024 10:57
Weekly Report: what happened at EDSA last week (1209-1213)?
Weekly Report · 12/16/2024 10:58
Edesa Biotech Reports Fiscal Year 2024 Financial Results and Updates on Strategic Initiatives
Barchart · 12/14/2024 01:56
Edesa Biotech Enhances Financial Position and Strategy
TipRanks · 12/13/2024 22:43
Based on the provided financial report article, the title of the article is likely: "10-K: ED SA Inc. (0001540159) (EDSA) - Management's Discussion and Analysis of Financial Condition and Results of Operations" This title is based on the fact that the article appears to be a 10-K filing with the Securities and Exchange Commission (SEC), which is an annual report that provides a comprehensive overview of a company's financial condition and results of operations. The title also includes the company name, ED SA Inc. (0001540159), and the ticker symbol EDSA.
Press release · 12/13/2024 22:30
Edesa Biotech GAAP EPS of -$1.93 beats by $0.22
Seeking Alpha · 12/13/2024 22:11
Edesa Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 12/13/2024 22:01
*Edesa Biotech: Cash, Cash Equivalents Totaled $1.0M at Year End 2024 >EDSA
Dow Jones · 12/13/2024 21:40
*Edesa Biotech: Op Expenses Down by $2.2M to $7.0 M for FY2024 >EDSA
Dow Jones · 12/13/2024 21:39
Edesa Biotech FY 2024 GAAP EPS $(1.93) Beats $(2.15) Estimate
Benzinga · 12/13/2024 21:31
*Edesa Biotech 2024 Loss/Shr $1.93 >EDSA
Dow Jones · 12/13/2024 21:31
EDESA BIOTECH REPORTS FISCAL YEAR 2024 RESULTS
Reuters · 12/13/2024 21:30
Press Release: Edesa Biotech Reports Fiscal Year 2024 Results
Dow Jones · 12/13/2024 21:30
More
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. It has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. It is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.